Sexual functioning in depressed outpatients taking mirtazapine

Beth K. Boyarsky, Waheedul Haque, Mark R. Rouleau, Robert M A Hirschfeld

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objectives - One-third of patients with untreated depression have sexual difficulties manifested by decreased libido, erectile dysfunction or delayed ejaculation. This dysfunction may be exacerbated by stimulation of post- synaptic serotonin 5HT2 receptors, a side-effect of most widely-used antidepressant medications, especially the selective serotonin reuptake inhibitors (SSRIs). Mirtazapine is an atypical antidepressant with α2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity. In theory, it should not worsen and perhaps may improve sexual function. This pilot study investigated sexual functioning and antidepressant activity in depressed patients taking mirtazapine. Experimental design - Twenty-five (F = 18, M = 7) sexually active adult outpatients with a DSM-IV- diagnosis of major depressive episode entered a 12-week, flexible-dosing, open-label pilot study. The Arizona Sexual Experiences Scale (ASEX) assessed sexual functioning and the Hamilton Depression Rating Scale (HAM-D) assessed depressive symptoms on a bimonthly basis. Principal Observations - Desire, arousal/lubrication, and ease/satisfaction of orgasm improved (by 41%, 52%, and 48%, respectively) in the depressed women. In men, desire, arousal/erection, and ease/satisfaction of orgasm also improved (by 10%, 23% and 14%, respectively) but much more modestly. HAM-D, Clinical Global Impression (CGI) Sheehan Disability Scale (SDS), and Symptom Checklist-90 (SCL-90) scores improved in both groups. There was a 50% dropout rate among women before six weeks of treatment. However, the ASEX and HAM-D scores of the groups terminating before and after six weeks of treatment showed similar rates of improvement. Conclusions - Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. Longer-term double-blind research assessing sexual function during the administration of mirtazapine as well as other antidepressants is recommended.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalDepression and Anxiety
Volume9
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Outpatients
Antidepressive Agents
Orgasm
Depression
Arousal
Second-Generation Antidepressive Agents
Lubrication
Receptors, Serotonin, 5-HT3
Libido
Ejaculation
Adrenergic Antagonists
Serotonin Receptors
Serotonin Uptake Inhibitors
Erectile Dysfunction
Checklist
Diagnostic and Statistical Manual of Mental Disorders
Serotonin
Research Design
mirtazapine
Therapeutics

Keywords

  • 5-HT2 serotonin antagonists
  • Alpha adrenergic antagonists
  • Depression
  • Sexual dysfunction antidepressants

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Sexual functioning in depressed outpatients taking mirtazapine. / Boyarsky, Beth K.; Haque, Waheedul; Rouleau, Mark R.; Hirschfeld, Robert M A.

In: Depression and Anxiety, Vol. 9, No. 4, 1999, p. 175-179.

Research output: Contribution to journalArticle

Boyarsky, Beth K. ; Haque, Waheedul ; Rouleau, Mark R. ; Hirschfeld, Robert M A. / Sexual functioning in depressed outpatients taking mirtazapine. In: Depression and Anxiety. 1999 ; Vol. 9, No. 4. pp. 175-179.
@article{c27ac9d5d0b14db8a58035f97d5111e4,
title = "Sexual functioning in depressed outpatients taking mirtazapine",
abstract = "Objectives - One-third of patients with untreated depression have sexual difficulties manifested by decreased libido, erectile dysfunction or delayed ejaculation. This dysfunction may be exacerbated by stimulation of post- synaptic serotonin 5HT2 receptors, a side-effect of most widely-used antidepressant medications, especially the selective serotonin reuptake inhibitors (SSRIs). Mirtazapine is an atypical antidepressant with α2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity. In theory, it should not worsen and perhaps may improve sexual function. This pilot study investigated sexual functioning and antidepressant activity in depressed patients taking mirtazapine. Experimental design - Twenty-five (F = 18, M = 7) sexually active adult outpatients with a DSM-IV- diagnosis of major depressive episode entered a 12-week, flexible-dosing, open-label pilot study. The Arizona Sexual Experiences Scale (ASEX) assessed sexual functioning and the Hamilton Depression Rating Scale (HAM-D) assessed depressive symptoms on a bimonthly basis. Principal Observations - Desire, arousal/lubrication, and ease/satisfaction of orgasm improved (by 41{\%}, 52{\%}, and 48{\%}, respectively) in the depressed women. In men, desire, arousal/erection, and ease/satisfaction of orgasm also improved (by 10{\%}, 23{\%} and 14{\%}, respectively) but much more modestly. HAM-D, Clinical Global Impression (CGI) Sheehan Disability Scale (SDS), and Symptom Checklist-90 (SCL-90) scores improved in both groups. There was a 50{\%} dropout rate among women before six weeks of treatment. However, the ASEX and HAM-D scores of the groups terminating before and after six weeks of treatment showed similar rates of improvement. Conclusions - Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. Longer-term double-blind research assessing sexual function during the administration of mirtazapine as well as other antidepressants is recommended.",
keywords = "5-HT2 serotonin antagonists, Alpha adrenergic antagonists, Depression, Sexual dysfunction antidepressants",
author = "Boyarsky, {Beth K.} and Waheedul Haque and Rouleau, {Mark R.} and Hirschfeld, {Robert M A}",
year = "1999",
doi = "10.1002/(SICI)1520-6394(1999)9:4<175::AID-DA5>3.0.CO;2-0",
language = "English (US)",
volume = "9",
pages = "175--179",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Sexual functioning in depressed outpatients taking mirtazapine

AU - Boyarsky, Beth K.

AU - Haque, Waheedul

AU - Rouleau, Mark R.

AU - Hirschfeld, Robert M A

PY - 1999

Y1 - 1999

N2 - Objectives - One-third of patients with untreated depression have sexual difficulties manifested by decreased libido, erectile dysfunction or delayed ejaculation. This dysfunction may be exacerbated by stimulation of post- synaptic serotonin 5HT2 receptors, a side-effect of most widely-used antidepressant medications, especially the selective serotonin reuptake inhibitors (SSRIs). Mirtazapine is an atypical antidepressant with α2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity. In theory, it should not worsen and perhaps may improve sexual function. This pilot study investigated sexual functioning and antidepressant activity in depressed patients taking mirtazapine. Experimental design - Twenty-five (F = 18, M = 7) sexually active adult outpatients with a DSM-IV- diagnosis of major depressive episode entered a 12-week, flexible-dosing, open-label pilot study. The Arizona Sexual Experiences Scale (ASEX) assessed sexual functioning and the Hamilton Depression Rating Scale (HAM-D) assessed depressive symptoms on a bimonthly basis. Principal Observations - Desire, arousal/lubrication, and ease/satisfaction of orgasm improved (by 41%, 52%, and 48%, respectively) in the depressed women. In men, desire, arousal/erection, and ease/satisfaction of orgasm also improved (by 10%, 23% and 14%, respectively) but much more modestly. HAM-D, Clinical Global Impression (CGI) Sheehan Disability Scale (SDS), and Symptom Checklist-90 (SCL-90) scores improved in both groups. There was a 50% dropout rate among women before six weeks of treatment. However, the ASEX and HAM-D scores of the groups terminating before and after six weeks of treatment showed similar rates of improvement. Conclusions - Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. Longer-term double-blind research assessing sexual function during the administration of mirtazapine as well as other antidepressants is recommended.

AB - Objectives - One-third of patients with untreated depression have sexual difficulties manifested by decreased libido, erectile dysfunction or delayed ejaculation. This dysfunction may be exacerbated by stimulation of post- synaptic serotonin 5HT2 receptors, a side-effect of most widely-used antidepressant medications, especially the selective serotonin reuptake inhibitors (SSRIs). Mirtazapine is an atypical antidepressant with α2 adrenergic antagonist and serotonin 5-HT2 and 5-HT3 receptor-blocking activity. In theory, it should not worsen and perhaps may improve sexual function. This pilot study investigated sexual functioning and antidepressant activity in depressed patients taking mirtazapine. Experimental design - Twenty-five (F = 18, M = 7) sexually active adult outpatients with a DSM-IV- diagnosis of major depressive episode entered a 12-week, flexible-dosing, open-label pilot study. The Arizona Sexual Experiences Scale (ASEX) assessed sexual functioning and the Hamilton Depression Rating Scale (HAM-D) assessed depressive symptoms on a bimonthly basis. Principal Observations - Desire, arousal/lubrication, and ease/satisfaction of orgasm improved (by 41%, 52%, and 48%, respectively) in the depressed women. In men, desire, arousal/erection, and ease/satisfaction of orgasm also improved (by 10%, 23% and 14%, respectively) but much more modestly. HAM-D, Clinical Global Impression (CGI) Sheehan Disability Scale (SDS), and Symptom Checklist-90 (SCL-90) scores improved in both groups. There was a 50% dropout rate among women before six weeks of treatment. However, the ASEX and HAM-D scores of the groups terminating before and after six weeks of treatment showed similar rates of improvement. Conclusions - Mirtazapine has a beneficial effect on sexual functioning in both depressed women and men. Longer-term double-blind research assessing sexual function during the administration of mirtazapine as well as other antidepressants is recommended.

KW - 5-HT2 serotonin antagonists

KW - Alpha adrenergic antagonists

KW - Depression

KW - Sexual dysfunction antidepressants

UR - http://www.scopus.com/inward/record.url?scp=0033017402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033017402&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6394(1999)9:4<175::AID-DA5>3.0.CO;2-0

DO - 10.1002/(SICI)1520-6394(1999)9:4<175::AID-DA5>3.0.CO;2-0

M3 - Article

VL - 9

SP - 175

EP - 179

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 4

ER -